The anti-infarct effect of an adenosine A1-selective agonist is diminished after prolonged infusion as is the cardioprotective effect of ischaemic preconditioning in rabbit heart

J Mol Cell Cardiol. 1994 Mar;26(3):303-11. doi: 10.1006/jmcc.1994.1039.

Abstract

Our aim was to determine whether adenosine A1 receptor-mediated protection could be maintained for a prolonged period of time by a continuous infusion of an A1-selective agonist. To produce myocardial infarction a branch of the left coronary artery of rabbit hearts was occluded for 30 min and reperfused for 3 h. Infarct size was determined with tetrazolium staining. Prior to the 30 min ischaemia, rabbits were subjected to one of the following six protocols: (1) 6 h i.v. saline infusion; (2) 6 h i.v. CCPA (0.043 mg/kg/h) infusion; (3) 72 h saline infusion; (4) 72 h CCPA infusion; (5) 72 h CCPA infusion plus preconditioning with 5 min ischaemia followed by 10 min reperfusion; (6) 72 h saline infusion plus preconditioning. The 6 h CCPA infusion group had significantly smaller infarct sizes than the 6 h vehicle group. 16.2 +/- 2.9% infarction of the ischaemic region v 39.5 +/- 2.6%, P < 0.01. Infarction in the 72 h CCPA infusion group (37.7 +/- 2.7%) was the same as in the 72 h vehicle group (35.2 +/- 3.1%). Ischaemic preconditioning could not limit infarct size in 72 h CCPA animals (%infarction; 29.1 +/- 4.6%) but did protect animals given vehicle for 72 h (8.4 +/- 1.2%, P < 0.01). After 72 h infusion of CCPA, both the cardioprotective effect of adenosine A1-selective agonist and ischaemic preconditioning were attenuated. These findings indicate that: (1) the myocytes become desensitized to the protective effect of CCPA with prolonged exposure; and (2) ischaemic preconditioning is no longer protective when tachyphylaxis to CCPA occurs.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylcholine / pharmacology
  • Adenosine / administration & dosage
  • Adenosine / analogs & derivatives*
  • Adenosine / blood
  • Adenosine / pharmacology
  • Adenosine / physiology*
  • Adenosine / therapeutic use
  • Animals
  • Bradycardia / chemically induced
  • Drug Tolerance
  • Female
  • Hemodynamics / drug effects*
  • Hypotension / chemically induced
  • Infusions, Intravenous
  • Male
  • Muscle Proteins / antagonists & inhibitors*
  • Muscle Proteins / physiology
  • Myocardial Infarction / pathology
  • Myocardial Infarction / prevention & control*
  • Myocardial Ischemia / physiopathology*
  • Myocardium / pathology
  • Necrosis
  • Purinergic P1 Receptor Antagonists*
  • Rabbits
  • Receptors, Muscarinic / drug effects
  • Receptors, Purinergic P1 / physiology

Substances

  • Muscle Proteins
  • Purinergic P1 Receptor Antagonists
  • Receptors, Muscarinic
  • Receptors, Purinergic P1
  • 2-chloro-N(6)cyclopentyladenosine
  • Adenosine
  • Acetylcholine